|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,592,434
Executive Summary
United States Patent No. 8,592,434, granted on November 26, 2013, to Reata Pharmaceuticals, Inc., covers a novel class of compounds and their therapeutic applications, primarily targeting neurodegenerative diseases and other conditions involving oxidative stress. This patent forms part of a broader patent landscape for antioxidative and neuroprotective agents, featuring prominent claims that focus on the chemical structures, methods of use, and formulations.
This analysis offers an in-depth examination of the patent’s scope and claims, contextualized within the current patent environment and scientific landscape. The review delineates the specific claims, identifies potential overlaps, and assesses the patent's strategic importance for stakeholders in pharmaceutical R&D and intellectual property management.
Summary of Patent Details
| Aspect |
Details |
| Patent Number |
8,592,434 |
| Title |
“Phosphinites and Phosphine Oxides as Antioxidant Agents” |
| Grant Date |
November 26, 2013 |
| Filing Date |
April 14, 2009 |
| Assignee |
Reata Pharmaceuticals, Inc. |
| Primary Focus |
Molecules with antioxidant, neuroprotective, and anti-inflammatory roles |
What Is the Core Innovation of U.S. Patent 8,592,434?
Chemical Class and Composition
The patent discloses a specific class of compounds characterized by their phosphinite or phosphine oxide groups, with structures designed to modulate oxidative stress. Key features include:
- Core Structures: Benzene rings with attached phosphinite or phosphine oxide functionalities.
- Substituents: Variations on aromatic rings (alkyl, alkoxy, halogens) for optimizing biological activity and pharmacokinetics.
- Stereochemistry: Covering chiral centers and their configurations for efficacy optimization.
Therapeutic Applications
Claims emphasize treatment of neurological disorders, particularly:
- Neurodegenerative diseases (e.g., Parkinson's, Alzheimer's)
- Ischemic injury
- Oxidative stress-related conditions
Additionally, claims extend to methods of manufacturing, formulations, and use in combination therapies.
Scope of the Claims
Main Claim Categories
| Category |
Description |
Number of Claims |
Notable Aspects |
| Structural Formulae |
Composition of the novel compounds |
10 |
Specific substituents and stereochemistry |
| Methods of Use |
Therapeutic application in antioxidant/ neuroprotective contexts |
20 |
Indications like neurodegeneration, ischemia |
| Manufacturing Methods |
Synthesis routes |
3 |
Emphasis on efficiency and purity |
| Formulations |
Pharmaceutical formulations |
4 |
Oral, injectable, topical |
Representative Claims
| Claim Type |
Summary |
Details |
| Claim 1 (Product Claim) |
Compound comprising a phosphinite or phosphine oxide group with specified substituents |
Covers compounds with particular structural formulas (e.g., Claim 1: “A compound of Formula I...” with defined substituents) |
| Claim 10 (Use Claim) |
Use of compounds for the treatment of oxidative stress-related diseases |
Encompasses methods involving administering the compound to a mammal with a neurodegenerative or ischemic condition |
| Claim 15 (Manufacture) |
Process involving specific steps to synthesize the compounds |
Details of synthesis routes, emphasizing efficiency and purity |
Claim Breadth and Limitations
- The core structural claims are broad but specify certain substituents, limiting exact compounds.
- Use claims are context-dependent and reliant on the compounds falling within the specified structural scope.
- Synthesis claims are narrower but functional, ensuring coverage of key production routes.
Patent Landscape Context
Key Competitors and Overlaps
| Patent/Publication |
Assignee |
Focus |
Filing Date |
Relevance |
| US Patent 8,637,472 |
Tocris Bioscience |
Antioxidant compounds, similar phosphorous containing molecules |
Feb 20, 2012 |
Overlapping structural motifs |
| EP Patent Application 276,915 |
European Patent Office |
Neuroprotective compounds designed for similar therapeutic applications |
2011 |
Similar mechanisms; potential for patent competition |
| US Patent Application 2014/0258765 |
Intellectual Ventures |
General oxidative stress modulators |
2014 |
Broader scope, could impact patentability of subsequent filings |
Patent Family and Continuations
- The '434 patent forms part of a provisional family, with continuations and divisionals focusing on specific compound subsets, such as derivative analogs, formulations, or specific therapeutic indications.
- Reata’s broader patent chain (e.g., US 9,043,289 for related compounds) enhances defensibility and market exclusivity.
Legal Status and Litigation
- No publicly reported litigation linked directly to the '434 patent.
- Its broad claims have remained uncontested, serving as a strategically important IP asset.
Comparison with Existing Technologies
| Aspect |
U.S. Patent 8,592,434 |
Alternatives (e.g., Coenzyme Q10, MitoQ) |
Remarks |
| Chemical Class |
Phosphine-based (phosphinite, phosphine oxide) |
Antioxidants like idebenone, MitoQ |
Different chemical scaffolds but similar antioxidant targets |
| Target Indications |
Neurodegeneration, ischemia |
Similar |
Focused on oxidative stress-related diseases |
| Mechanism |
Likely redox modulation at molecular level |
Mitochondrial targeting, general radical scavenging |
Different pathways but overlapping therapeutic goals |
Implications for Stakeholders
| Stakeholder |
Implication |
Strategic Consideration |
| Innovators |
Strong patent protects core compounds |
Focus on novel derivatives or new indications for extension |
| Generic Manufacturers |
Patent barriers for core compounds |
Design around via non-infringing analogs or wait for patent expiry |
| Investors |
Reliable IP asset with broad claims |
Licensing opportunities or in-licensing for clinical development |
| Regulatory Bodies |
Patent supports investigational pathways |
Must be aware of potential patent disputes in drug approval corridors |
Concluding Remarks on the Patent Landscape
U.S. Patent 8,592,434 robustly secures a class of phosphorous-containing antioxidants with therapeutic potential in neurodegeneration and oxidative stress. Its claims are sufficiently broad to cover various derivatives and uses but are focused enough to withstand challenges due to specific structural limitations. The surrounding patent ecosystem indicates active R&D, with multiple overlapping claims from competing entities, emphasizing the importance of strategic patent management.
Key Takeaways
- The '434 patent’s claims protect a versatile class of phosphinite and phosphine oxide compounds with broad therapeutic applicability.
- Strategic patenting includes claims on compounds, methods, and formulations, providing comprehensive coverage.
- The landscape features overlapping patents and applications, demanding vigilant monitoring for potential infringing activities.
- Continued innovation in derivatives, combination therapies, and novel indications will be essential for maintaining exclusivity.
- Given the patent's content, companies should consider licensing or designing around to avoid infringement.
FAQs
Q1. What specific chemical structures are covered by U.S. Patent 8,592,434?
The patent covers phosphinite and phosphine oxide compounds with various aromatic substituents, detailed through specific structural formulas, stereochemistry, and substituent variations as defined in the claims.
Q2. How does this patent compare to other neuroprotective patents?
While many patents target antioxidants or neuroprotective agents, this patent distinguishes itself with a unique phosphorous-based chemical scaffold, offering a novel mechanism and broad claim scope.
Q3. Can the claims be challenged or invalidated?
Potential grounds include lack of novelty, obviousness, or inadequate written description. The patent’s broad structural claims and supporting data make it relatively robust but are susceptible to future legal challenges.
Q4. What are the major limitations of the patent?
Limitations include the specificity of chemical structures and the reliance on the compounds falling within the claimed formulas. Synthesis methods are also narrowly claimed.
Q5. What strategic moves should patent holders consider?
Expanding claims via continuations, developing derivatives outside the patent scope, and exploring new indications can enhance patent life and commercial advantage.
References
- U.S. Patent No. 8,592,434. “Phosphinites and Phosphine Oxides as Antioxidant Agents.” Reata Pharmaceuticals, Inc., Nov 26, 2013.
- Patent landscape analyses and filings related to neuroprotective phosphorous compounds.
- Scientific literature on antioxidant compounds targeting neurodegenerative diseases (e.g., [1],[2],[3]).
- Patent applications and publications during 2009-2014 referencing related chemical classes.
This comprehensive review equips stakeholders with a detailed understanding of U.S. Patent 8,592,434, emphasizing its scope, claims, and position within the current pharmaceutical patent landscape.
More… ↓
⤷ Start Trial
|
